Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\39086890
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 World+J+Cardiol
2024 ; 16
(7
): 370-379
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Recent advances in the diagnostic methods and therapeutic strategies of
transthyretin cardiac amyloidosis
#MMPMID39086890
Kourek C
; Briasoulis A
; Magouliotis DE
; Georgoulias P
; Giamouzis G
; Triposkiadis F
; Skoularigis J
; Xanthopoulos A
World J Cardiol
2024[Jul]; 16
(7
): 370-379
PMID39086890
show ga
Cardiac amyloidosis is a progressive disease characterized by the buildup of
amyloid fibrils in the extracellular space of the heart. It is divided in 2 main
types, immunoglobulin light chain amyloidosis and transthyretin amyloidosis
(ATTR), and ATTR amyloidosis is further divided in 2 subtypes, non-hereditary
wild type ATTR and hereditary mutant variant amyloidosis. Incidence and
prevalence of ATTR cardiac amyloidosis is increasing over the last years due to
the improvements in diagnostic methods. Survival rates are improving due to the
development of novel therapeutic strategies. Tafamidis is the only
disease-modifying approved therapy in ATTR amyloidosis so far. However, the most
recent advances in medical therapies have added more options with the potential
to become part of the therapeutic armamentarium of the disease. Agents including
acoramidis, eplontersen, vutrisiran, patisiran and anti-monoclonal antibody NI006
are being investigated on cardiac function in large, multicenter controlled
trials which are expected to be completed within the next 2-3 years, providing
promising results in patients with ATTR cardiac amyloidosis. However, further and
ongoing research is required in order to improve diagnostic methods that could
provide an early diagnosis, as well as survival and quality of life of these
patients.